ReviewCurrent atherosclerosis reports2010
Evidence for aggressive blood pressure-lowering goals in patients with coronary artery disease.
Review in Current atherosclerosis reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.The Cochrane database of systematic reviews · 2022Pooled it
- Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.The Cochrane database of systematic reviews · 2020Pooled it
- Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.The Cochrane database of systematic reviews · 2018Pooled it
- Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.The Cochrane database of systematic reviews · 2017Pooled it
- Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.Mayo Clinic proceedings · 2011Review
- Establishing targets for hypertension control in patients with comorbidities.Current hypertension reports · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lowering blood pressure (BP) reduces the risk of major cardiovascular mortality and morbidity. Current consensus targets for BP reduction are less than 140/90 mm Hg in uncomplicated hypertension and less than 130/80 mm Hg in those patients with diabetes, chronic kidney disease, and coronary artery disease or in those who are at high risk for developing coronary artery disease (defined as a Framingham risk score of > or = 10%). There is solid epidemiologic evidence for lower BP targets, supported by some clinical studies with surrogate end points. On the other hand, there are meager data from clinical trials using hard end points, and there is a concern that overly aggressive BP lowering, especially of diastolic BP, may impair coronary perfusion, particularly in patients with left ventricular hypertrophy and/or coronary artery disease. This review evaluates the evidence for the benefit of lower BP targets in hypertension management.
Indexed as
Identifiers
20425249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.